Promising Data on CG Oncology’s Cretostimogene Justifies Buy Rating
I'm PortAI, I can summarize articles.
JonesTrading analyst Soumit Roy has reiterated a Buy rating for CG Oncology's stock due to promising data on their bladder cancer treatment, cretostimogene. The treatment has shown impressive results in high-grade non-muscle invasive bladder cancer, outperforming competitors and standard care options. Positive data readouts have addressed previous concerns, and ongoing trials are expected to further solidify its market position.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments